Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

Study of GS-0272 in Participants With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT06031415

Public ClinicalTrials.gov record NCT06031415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Ascending Doses of GS-0272 in Adult Participants With Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.

Study identification

NCT ID
NCT06031415
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
55 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 27, 2023
Primary completion
May 10, 2026
Completion
May 10, 2026
Last update posted
May 26, 2026

2023 – 2026

United States locations

U.S. sites
14
U.S. states
6
U.S. cities
14
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Associates P.C. Glendale California 85306
Stanford School of Medicine, Division of Immunology & Rheumatology Palo Alto California 94304
1238 E. Arrow Hwy Upland California 91786
Clinical Research of West Florida, Inc. Clearwater Florida 33765
Jacksonville Center for Clinical Research Jacksonville Florida 32216
Greater Chicago Specialty Physicians/ Clinical Investigation Specialists Niles Illinois 60714
Greater Chicago Specialty Physicians/Clinical Investigation Specialists, Inc. Schaumburg Illinois 60195
Summit Headlands LLC Portland Oregon 97210
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
PA Regional Center for Arthritis and Osteoporosis Research Wyomissing Pennsylvania 19610
Precision Comprehensive Clinical Research Solutions Colleyville Texas 76034
Accurate Clinical Research, Inc. Houston Texas 77089
Precision Comprehensive Clinical Research Solutions Irving Texas 75061
1600 Republic Parkway Mesquite Texas 75150

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06031415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 26, 2026 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06031415 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →